KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Operating Expenses (2019 - 2025)

Historic Operating Expenses for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $233.6 million.

  • Royalty Pharma's Operating Expenses rose 63.8% to $233.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $818.7 million, marking a year-over-year decrease of 1569.9%. This contributed to the annual value of $818.7 million for FY2025, which is 1569.89% down from last year.
  • Latest data reveals that Royalty Pharma reported Operating Expenses of $233.6 million as of Q4 2025, which was up 63.8% from $182.1 million recorded in Q3 2025.
  • Over the past 5 years, Royalty Pharma's Operating Expenses peaked at $1.0 billion during Q4 2022, and registered a low of -$190.0 million during Q2 2021.
  • Moreover, its 5-year median value for Operating Expenses was $275.2 million (2021), whereas its average is $272.1 million.
  • Per our database at Business Quant, Royalty Pharma's Operating Expenses plummeted by 28701.99% in 2021 and then soared by 147940.93% in 2024.
  • Quarter analysis of 5 years shows Royalty Pharma's Operating Expenses stood at $422.3 million in 2021, then skyrocketed by 148.27% to $1.0 billion in 2022, then tumbled by 101.61% to -$16.8 million in 2023, then soared by 1479.41% to $232.1 million in 2024, then grew by 0.64% to $233.6 million in 2025.
  • Its Operating Expenses was $233.6 million in Q4 2025, compared to $182.1 million in Q3 2025 and $368.9 million in Q2 2025.